Detalhe da pesquisa
1.
Zanubrutinib in relapsed/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study.
Blood
; 139(21): 3148-3158, 2022 05 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-35303070
2.
A two-part, single-arm, multicentre, phase I study of zanubrutinib, a selective Bruton tyrosine kinase inhibitor, in Chinese patients with relapsed/refractory B-cell malignancies.
Br J Haematol
; 198(1): 62-72, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35383885
3.
Zanubrutinib monotherapy for relapsed or refractory non-germinal center diffuse large B-cell lymphoma.
Blood Adv
; 6(6): 1629-1636, 2022 03 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-34638136
4.
Tislelizumab for Relapsed/Refractory Classical Hodgkin Lymphoma: 3-Year Follow-up and Correlative Biomarker Analysis.
Clin Cancer Res
; 28(6): 1147-1156, 2022 03 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-34716199
5.
Pooled safety analysis of zanubrutinib monotherapy in patients with B-cell malignancies.
Blood Adv
; 6(4): 1296-1308, 2022 02 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-34724705
6.
YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo.
Cancer Sci
; 102(7): 1374-80, 2011 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-21443688
7.
PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib.
BMC Cancer
; 11: 248, 2011 Jun 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-21676217
8.
A Phase II Trial of the Bruton Tyrosine-Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Relapsed/Refractory Waldenström Macroglobulinemia.
Clin Cancer Res
; 27(20): 5492-5501, 2021 10 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-34253577
9.
Biomarker alterations with metronomic use of low-dose zoledronic acid for breast cancer patients with bone metastases and potential clinical significance.
Breast Cancer Res Treat
; 124(3): 733-43, 2010 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-20882405
10.
Safety and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor YN968D1 in patients with advanced malignancies.
BMC Cancer
; 10: 529, 2010 Oct 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-20923544
11.
Protective Effect of Vitamin C against Infancy Rat Corneal Injury Caused by Acute UVB Irradiation.
Biomed Res Int
; 2020: 8089273, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-32596375
12.
Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with the BTK inhibitor zanubrutinib: phase 2, single-arm, multicenter study.
J Hematol Oncol
; 13(1): 48, 2020 05 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32393328
13.
Treatment of Patients with Relapsed or Refractory Mantle-Cell Lymphoma with Zanubrutinib, a Selective Inhibitor of Bruton's Tyrosine Kinase.
Clin Cancer Res
; 26(16): 4216-4224, 2020 08 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32461234
14.
Treatment of relapsed or refractory classical Hodgkin lymphoma with the anti-PD-1, tislelizumab: results of a phase 2, single-arm, multicenter study.
Leukemia
; 34(2): 533-542, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31520078
15.
Primary non-Hodgkin's lymphoma of the breast: eight-year follow-up experience.
Int J Hematol
; 87(5): 491-497, 2008 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-18414980
16.
[Prognosis of primary non-Hodgkin's lymphoma of the breast].
Zhonghua Zhong Liu Za Zhi
; 30(3): 200-2, 2008 Mar.
Artigo
em Zh
| MEDLINE | ID: mdl-18756936
17.
Zanubrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma: final results and correlative analysis of lymphocytosis.
Leuk Lymphoma
; 64(3): 712-716, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36799536
18.
A phase II study of Zanubrutinib in combination with rituximab in patients with relapsed/refractory aggressive and indolent B-cell lymphoma.
Leuk Lymphoma
; 63(10): 2503-2506, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35855547
19.
Population Pharmacokinetic and Pharmacodynamic Modeling and Effects on Platelet Counts of Different Dosages of Eltrombopag in Chinese Patients With Chronic Primary Immune Thrombocytopenia.
Clin Ther
; 37(7): 1382-95, 2015 Jul 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-25929594
20.
S-1 monotherapy as second line chemotherapy in advanced gastric cancer patients previously treated with cisplatin/infusional fluorouracil.
Int J Clin Exp Pathol
; 7(6): 3293-8, 2014.
Artigo
em Inglês
| MEDLINE | ID: mdl-25031751